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Abstract
Background: Lentiviral gene transfer can provide long-term expression of therapeutic genes such as erythropoietin.
Because overexpression of erythropoietin can be toxic, regulated expression is needed. Doxycycline inducible vectors can
regulate expression of therapeutic transgenes efficiently. However, because they express an immunogenic transactivator
(rtTA), their utility for gene therapy is limited. In addition to immunogenic proteins that are expressed from inducible
vectors, injection of the vector itself is likely to elicit an immune response because viral capsid proteins will induce ‘‘danger
signals’’ that trigger an innate response and recruit inflammatory cells.
Methodology and Principal Findings: We have developed an autoregulatory lentiviral vector in which basal expression of
rtTA is very low. This enabled us to temporally separate the injection of virus and the expression of the therapeutic gene
and rtTA. Wistar rats were injected with an autoregulatory rat erythropoietin expression vector. Two or six weeks after
injection, erythropoietin expression was induced by doxycycline. This resulted in an increase of the hematocrit, irrespective
of the timing of the induction. However, most rats only responded once to doxycycline administration. Antibodies against
rtTA were detected in the early and late induction groups.
Conclusions: Our results suggest that, even when viral vector capsid proteins have disappeared, expression of foreign
proteins in muscle will lead to an immune response.
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Introduction
Many forms of gene therapy will require the ability to modulate
the expression of therapeutic genes to maintain expression levels
within a therapeutic window or adjust expression levels based on
disease progression within the patient [1]. Lentiviral vectors
derived from HIV-1 are a well-suited vehicle for the treatment of a
variety of inherited and acquired diseases. They can deliver a
relatively large therapeutic cassette into both dividing and non-
dividing cells and integrate into the host cell genome providing life
long expression of the therapeutic gene [2–4].
Because the tetracycline (Tet-On) inducible system [5] has been
extensively used to regulate gene expression in vitro and in vivo [6–8],
it is an attractive candidate to develop regulated gene therapy. The
Tet-On system is composed of a chimeric reverse tetracycline
transactivator (rtTA) composed of the herpesvirus VP16 tran-
scription activating domain and a mutant tetracycline repressor
protein from Escherichia coli. Furthermore, the system contains a
minimal CMV promoter fused to several copies of the tetracycline
operator sequence (tetO). In the presence of tetracycline
or doxycycline, rtTA binds to the tetO and thus initiates
transcription.
Early versions of the Tet-On system required high concentra-
tion of doxycycline for activation (100 ng/ml to 1000 ng/ml),
which are easily obtained in cell culture but not in vivo. Novel rtTA
variants derived from viral evolution were recently described that
are responsive to as little as 10 ng/ml doxycycline [9], making
them potentially better suited for in vivo use.
Although there have been significant improvements made in the
basal activity and sensitivity of rtTA, this chimeric bacterial and
viral protein can be a potent immunogen. Indeed, in studies
performed in mice [10] and non-human primates [11,12], the
development of rtTA antibodies and cytotoxic T cell mediated
clearance of rtTA expressing cells was observed.
Immune responses to therapeutic proteins and clearance of
corrected cells is a major obstacle to the clinical implementation of
gene therapy. The Danger Model proposed by Matzinger suggests
that the immune system does not function solely based on
detection of self and non-self, but additionally requires a danger
signal to activate antigen presenting cells (APC) leading to an
immune response [13,14]. The Danger Model predicts that
presentation of the antigen in the absence of danger signals would
lead to either elimination or anergization of T cells and induce a
temporary state of tolerance. In regards to gene therapy, the
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proteins and is a potent trigger for the activation of danger signals
[15].
We have previously described a single Tet-on inducible
lentiviral vector with autoregulatory expression of rtTA [16]. This
vector is characterised by very low basal expression levels of rtTA
in the absence of doxycycline stimulation. Only when doxycycline
is administrated, expression of rtTA and the therapeutic or marker
gene is induced[16].
Mathematical modelling predicts that this type of synthetic gene
circuit exhibits bimodal expression; the regulated gene can only be
in a ‘‘on’’ or ‘‘off’’ state, without intermediary expression levels,
and this was indeed verified experimentally[17]. However, the
absolute magnitude of expression levels will vary between
individual integrated vector genomes[17].
We showed in cell culture that our autoregulatory vector has
lower background and higher induction than vectors in which
there is constitutive expression of rtTA[16]. This vector also
performed better in vivo in immunocompromised mice. Human
hematopoietic stem cells were transduced with an autoregulatory
or constitutive rtTA vector and transplanted into immune
deficient mice[18]. Only cells transduced with the autoregulatory
vector differentiated into multiple lineages and several cycles of
GFP expression could be induced by doxycycline administra-
tion[18].
These data indicate that autoregulatory lentiviral vectors
perform better than vectors in which there is constitutive
expression of rtTA. Likely because constitutive expression of rtTA
is toxic and also leads to higher background expression of the
regulated gene.
We have previously shown that lentiviral vectors can be used for
the stable long term expression of erythropoietin (Epo) in rats [19].
Erythropoietin gene therapy would be an alternative to treatment
with recombinant Epo in patients with kidney failure. However,
because over expression of Epo and the resulting high hematocrits
will lead to a variety of clinical problems, Epo gene therapy must
be carefully regulated.
To test our autoregulatory lentiviral vector system with a
therapeutic gene in immunocompetent animals, we constructed an
inducible rat Epo vector. This allowed us to determine if induction
of rtTA expression in absence of the danger signals associated with
the injection of viral particles, would avoid an immune response to
rtTA and allow for repeated rounds of doxycycline stimulation.
Results
Construction and in vitro evaluation of TREAutoR4rEPO
Our previously described single doxycycline inducible lentiviral
vector TREAutoR3 [16] was modified by replacing the d2eGFP
gene with the cDNA coding for rat erythropoietin and
introduction of a novel rtTA variant, V16 (V9I F67S R171K)
[9] with a 10 fold increased sentivity to doxycycline to make
TREAutoR4rEPO. We selected a rat muscle cell line, H9C2, to
evaluate the function of the system in vitro. H9C2 cells were
transduced with concentrated TREAutoR4rEPO virus and
allowed to expand. Following expansion, cells were stimulated
with 10 ng/ml doxycycline and 72 hours later media was collected
and cell lysates were prepared to determine basal and induced
EPO and rtTA expression levels respectively. Western blot of
H9C2 cell lysates showed undetectable levels of rtTA expression in
the absence of doxycycline (Figure 1 lane 3), rtTA expression was
only detected following treatment with 10 ng/ml doxycycline
(Figure 1 lane 4). Control cells showed no detectable rtTA
expression in the absence or presence of doxycycline (Figure 1
lanes 1). Epo was not detected in the media of mock transduced
cells. (Figure 1 lower panel lanes 1 and 2). A low basal level of Epo
was detected in the media of unstimulated cells transduced with
the TREAutoR4rEPO vector (Figure 1 lower panel lane 3).
Following stimulation with 10 ng/ml doxycycline we detected an
strong increase in Epo levels (Figure 1 lower panel lanes 4) of 53
fold.
Constitutive expression of rat Epo
We previously demonstrated long term expression of Epo
delivered by an intramuscular injection of a lentiviral vector in
Fisher 344 rats [19]. To confirm similar long-term expression in
Wistar rats, a lentiviral vector with a constitutive CMV promoter
driving expression of Epo was injected into the hind leg of Wistar
rats and blood samples were collected every two weeks. An
increase in hematocrit was observed two weeks following virus
injection to 60%, reaching a plateau level of approximately 75%
by week ten (Figure 2), confirming long term Epo expression.
These data indicate that lentiviral vectors with constitutive
expression of rat Epo are not silenced or cleared by the immune
system in rat muscle.
Inducible expression or rat Epo
In total 16 rats received an IM injection of 0.4ug p24 of
TREAutoR4rEPO virus in 100 ml PBS into the right hind leg. The
animals were divided into two groups: early induction, receiving
doxycycline in the drinking water two weeks following virus
injection, and late induction getting doxycycline in the drinking
water six weeks following virus injection. One rat from the early
induction group and two from the late induction group did not
have any response to doxycycline stimulation and were classified
as non-responders. Blood was collected every two weeks for
hematocrit determination. Two weeks following doxycycline
administration the average hematocrit of the early induction
group increased from 51% to 67% (Figure 3). Unexpectedly, after
four weeks of doxycycline treatment the average hematocrit
dropped down to 59%. Since the mean life span of erythrocytes in
the Wistar rat is approximately 60 days [20], this rapid decrease in
Figure 1. In vitro regulation of Epo expression in H9c2 rat
myoblasts. A Western blot on control and transduced H9c2 cells was
performed to detect rtTA expression. Expression of actin was used as a
loading control. Simultaneously, the corresponding levels of Epo
secreted into the cell culture media were measured by ELISA and are
reported as mIU/mL below the Western blot. Lanes 1 and 2 control
H9c2 lysates, 3 and 4 H9c2 cells transduced with TREAutoR4rEPO. Lanes
2 and 4 contain lysates of cells that were induced by the addition of
doxycycline.
doi:10.1371/journal.pone.0009974.g001
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after initiation of doxycycline administration. At the four and six
week time points there was a significant difference (p,0.005) in
hematocrit between untreated and doxycycline treated rats. A
second round of stimulation with doxycycline was performed ten
weeks following virus injection and no change in hematocrit was
detected in all rats in the early induction group.
At six weeks following virus injection the early induction group
was placed on normal water while the late induction group received
its first doxycycline in the drinking water for a period of four weeks.
Two weeks following doxycycline stimulation we observed an
increase in hematocrit in the late induction group to approximately
62% (p,0.005) compared to virus injected rats on normal water.
Because the magnitude in increase in hematocrit of the early and
late induction groups were comparable, this demonstrated that
transduced, non-induced cells persist for six weeks without being
eliminated or silenced. As with the early induction group, we
observed a rapid decrease in hematocrit after four weeks treatment
Figure 2. Constitutive lentiviral expression of Epo. Wistar rats were injected with CMV Epo (n=11) or vehicle (n=2) at t=0. A sustained
elevated hematocrit was observed in all CMV Epo injected animals.
doi:10.1371/journal.pone.0009974.g002
Figure 3. Inducible lentiviral expression of Epo. Wistar rats were injected with TREAutoR4rEpo at t=0. Early induction rats (n=7) were given
doxycycline in the drinking water for two periods of four weeks starting at weeks 2 and 10 (solid line). Late induction rats (n=5) were given
doxycycline in the drinking water for two periods of four weeks starting at weeks 6 and 14 (dashed line). The solid and dashed lines below indicate
the starting points for doxycycline administration for the early and late induction groups respectively. * Indicates a statistical significant difference
p,0.05 between the early and late induction groups.
doi:10.1371/journal.pone.0009974.g003
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cells upon induction of Epo expression. A second round of
doxycycline stimulation at week 14 failed to raise hematocrit levels
as observed with the early induction group (Figure 3).
Interestingly, one rat, R15, within the late induction group was
capable of undergoing multiple rounds of induction with
doxycycline (Figure 4) and was not included in the data analysis
for the late induction group. The kinetics of hematocrit changes of
this rat were also markedly different. High hematocrits were
maintained longer after doxycycline administration was halted.
These observations provide more evidence that the rapid decrease
in hematocrits in most animals induced by doxycycline was due to
elimination of transduced cells.
Detection of rtTA antibodies in plasma is independent of
early or late induction
Plasma from rats at two, six, and ten weeks after viral injection
was analyzed for the presence of rtTA antibodies in the early
induction, late induction, and non-responder groups. No antibod-
ies were detected in the plasma of animals from each group at the
two weeks time point. At the ten week time point no difference was
seen in the total number of animals positive for rtTA antibodies
between the early and late induction groups (Table 1). This
suggests that there is no benefit in delaying induction for
preventing a humoral immune response.
Influx of immune cells detected within the area of viral
injection
Rats were injected with a lentiviral GFP vector to better
understand the local immunological response to an intramuscular
injection. Animals were sacrificed at one and two weeks following
injection and muscle was collected for immunostaining with an
antibody directed against rat CD45 to detect the presence of
infiltrating immune cells. One week following lentiviral vector
injection we observed massive infiltration of CD45 positive cells in
areas with remnants of GFP expression. (Figure 5A,B) and not in
areas negative for GFP expression (Figure 5C) or in the PBS
injected muscle (Figure 5D). Only punctuate GFP expression was
detected, these are likely remnants of GFP expressing muscle cells.
The muscle tissue with immune cell infiltration appeared
damaged, also suggesting the clearance of transduced cells. No
GFP positive muscle cells were detected two weeks following viral
injection (data not shown). These data indicate that rats do mount
a vigorous immune response to immunogenic antigens delivered
by lentiviral vectors.
Discussion
The ability to regulate the expression level of a therapeutic gene
is vital for the advancement of gene therapy into the clinic. In
addition to concerns over safety, expression levels of the
therapeutic gene may require modulation in response to the
disease progression of the patient[1]. Lentiviral vector mediated
gene therapy is well suited for the long-term expression of a
therapeutic gene. We have previously described an autoregulatory
lentiviral vector that uses the tetracycline inducible system and is
characterised by low basal expression of rtTA and regulated genes
in the absence of doxycycline stimulation [16]. To test our system
with a therapeutically relevant gene in vivo we constructed a vector
in which Erythropoietin (Epo) expression could be regulated. This
vector also included a new rtTA variant [9] which is 100 times
more sensitive to doxycycline than the originally described rtTA.
We confirmed that by using this vector rtTA protein expression
was undetectable on western blot of transduced muscle cells in the
absence of doxycycline (Figure 1). We also showed that this vector
mediates a robust induction of the therapeutic gene Epo in vitro.
Wistar rats were injected with the inducible Epo vector and
doxycycline was administrated two weeks (early induction) or six
weeks (late induction) after vector injection.
In both early and late and induction groups we observed a
similar pattern, an initial increase in hematocrit at two weeks
following doxycycline treatment followed by a reduction in
hematocrit levels at four weeks on doxycycline (Figure 3). Given
that the estimated life span of Wistar rat erythrocytes is 59 days
Figure 4. Multiple cycles of Epo expression. Wistar rats were injected with TREAutoR4rEpo at t=0. Rats were given doxycycline in the drinking
water for three periods of four weeks starting at weeks 6, 18 and 28 (solid line). In one rat (R15), hematocrits could be increased with each of three
successive rounds of doxycycline administration. The cage and litter mate (R16) only responded once to doxycycline.
doi:10.1371/journal.pone.0009974.g004
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administration there is a rapid loss in exogenously expressed
Epo. Silencing of vector is unlikely since rats injected with a
constitutive Epo vector show long term expression without
reduction in therapeutic effect (Figure 2) and because rats can
be induced as efficiently two or six weeks after vector injection.
Furthermore, in human hematopoietic cells grafted in immune
deficient mice, multiple rounds of induction with a comparable
autoregulatory GFP vector are also possible[18].
The most likely explanation of the loss of Epo expressing cells is
therefore an cytotoxic immune response against the transduced
muscle cells. This hypothesis is strengthened by the appearance of
antibodies to rtTA in the injected animals. However, only direct
detection of rtTA specific cytotoxic T cells will conclusively prove
that the loss of Epo expression is immune mediated.
Interestingly, one animal in the late induction group was
capable of undergoing multiple inductions (Figure 4), while the
other animals were not responsive to a second round of
doxycycline stimulation (Figure 3). Whether this was a conse-
quence of the late induction is unclear and will require further
investigations. No difference was observed in the development of
antibodies against rtTA between non-responders, early induction,
and late induction groups at ten weeks following virus injection
(Table 1). This suggests that delaying induction has no benefit for
the prevention of a humoral immune response.
A strong immune response was observed following intramuscu-
lar injected lentiviral vector expressing GFP. Muscle harvested one
week following vector injection showed sporadic expression of
GFP that was accompanied by massive infiltration of immune cells
(Figure 5A and 5B). No GFP positive cells or areas of infiltrating
immune cells were detected in an animal sacrificed two weeks
following vector injection (data not shown), further suggesting a
rapid clearance of GFP expressing muscle cells. These data show
that rats have a vigorous immune response to lentiviral vectors
expressing GFP from a ubiquitous promoter and might be a better
animal model for pre clinical gene therapy studies than the
commonly used murine models.
Several factors, including contaminants from the concentration
of viral preparation [21] and efficient transduction of professional
antigen presenting cells (APC) [22,23], may play a role in the short
term expression observed following intramuscular injection of
lentiviral vectors. Introduction of muscle specific promoters have
been shown to improve long term adenoviral [24] and AAV [25]
mediated expression. A muscle specific promoter driving rtTA
expression was required to obtain long term regulation using an
adenoviral vector [26]. Together, this suggests that gene transfer to
antigen presenting cells within the muscle and subsequent
expression and presentation of the transgene may be a critical
factor in the initiation of an immune response.
In summary, we have shown that the low basal level of rtTA
expressed in our autoregulatory vector is not sufficient to avoid an
immune response to rtTA.
Our results therefore suggest that danger signals associated with
the injection of a viral vector are not essential for the development
of an immune response. However, since our autoregulatory vector
has, by definition, a low level of basal expression, we therefore
cannot completely exclude the possibility that the immune system
is primed at the moment of injection.
Further modifications are required to translate this system into
clinical applications.
Materials and Methods
Plasmid construction
The constitutive rat Epo lentiviral vector was constructed by
cloning rat Epo as an EcoR1 fragment in prrlcpptCMVPRE[27].
An expression plasmid containing the rtTA variant V16 (V9I
F67S R171K), rtTA4, was digested with XbaI and XmaI and
subcloned into a XbaI and XmaI digest of pRRLcpptMCSIR-
ESrtTA3LTRTetO to make pRRLcpptMCSIRESrtTA4LTR-
TetO and was verified by sequencing. An expression plasmid for
d2eGFP and pRRLcpptMCSIRESrtTA4LTRTetO were digest-
ed with BamHI and EcoRI and the resulting d2eGFP fragment
was cloned into pRRLcpptMCSIRESrtTA4LTRTetO to make
pRRLcpptd2eGFPIRESrtTA4LTRTetO. A BamHI and EcoRV
digest was performed to liberate a fragment containing
d2eGFPIRESrtTA4 and was subcloned into a BamHI and
Table 1. Antibodies directed against rtTA.
Weeks following virus administration
Group 2 6 10
Early Induction (n=3) 0/3 2/3 3/3
Late Induction (n=3) 0/3 1/3 3/3
Non responders (n=2) 0/2 2/2 2/2
Eight animals were analyzed for the presence of circulating antibodies to rtTA
by ELISA.
At 2 weeks following virus administration no animals had received doxycycline.
At 6 weeks the Early induction group had been given doxycycline in the
drinking water for 4 weeks and were subsequently placed on normal water. At
10 weeks the Late induction group had been given doxycycline in the drinking
water for 4 weeks. The Non responders consist of one animal each from the
Early and Late induction groups.
All animals developed antibodies to rtTA.
doi:10.1371/journal.pone.0009974.t001
Figure 5. Histochemistry of rat muscle injected with GFP
lentiviral vector. Wistar rats were injected with a lentiviral GFP
expression vector (A-C) or saline control (D). (A,B) Areas with remnants
of GFP expressing cells (green) show co-localization with CD45 stained
(red) infiltrating immune cells. (C) Areas without GFP expression within
the same piece of tissue are devoid of infiltrating immune cells. (D)
Control injected muscle is negative for both GFP expression and
infiltrating immune cells.
doi:10.1371/journal.pone.0009974.g005
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AgeI and XhoI digest was performed on pBSK d2eGFPIR-
ESrtTA4 and TREAutoR3 and the new fragment d2eGFPIR-
ESrtTA4 was cloned into the TREAutoR3 backbone to make
TREAutoR4. The gene coding for rat erythropoietin was
recovered by an EcoRI digest of the pRRLcpptCMVEpo plasmid
cloned into the backbone of an EcoRI digest of TREAutoR4 to
make TREAutoR4rEPO.
Cell lines and culturing
Human embryonic kidney (HEK) 293T, HeLa, and H9c2 rat
DB1X heart myoblasts were originally obtained from ATCC
(http://www.atcc.org/), cultured in standard DMEM supplement-
ed with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM glutamine at 37uC in 10% CO2.
Lentiviral vector preparation
Lentiviral vectors were produced as previously reported [27].
Briefly, HEK 293T cells were transiently transfected by calcium
phosphate precipitation using a third generation lentiviral vector
system [28,29]. Twenty-four hours following transfection, fresh
media supplemented with 25 mM HEPES buffer pH 7.4 was
added. Virus containing supernatent was harvested 48 and
72 hours following transfected, filtered through 0.45 mm Millipore
filters and concentrated by ultra centrifugation using a Beckman
SW-28 rotor 20,000 RPM for 2 hours at 4uC. Viral pellets were
resuspended in PBS and frozen at 280uC.
Viral transduction
The p24 antigen content of concentrated TREAutoR4rEpo
lentivirus was determined using a commercial ELISA kit from
Perkin Elmer (NEK050A). H9C2 cells were seeded out at 1610
5
per well and were transduced for four hours in the presence of
10 mg/ml DEAE Dextran. Gene expression was induced by the
addition of 10 ng/ml doxycycline (Sigma). Epo secretion into
media was determined using a commercial ELISA kit from R&D
Systems (DEP00). Viral titers of LVpgkGFP were determined by
serial dilution on HeLa cells. GFP expression in transduced HeLa
cells was determined by flow cytometry 72 hours following
transduction.
Ethics statement
All animal experiments were performed approved by the
Animal Ethical Committee at the Academic Medical Center of
Amsterdam.
Intramuscular injection of CMV rEPO, TREAutoR4rEPO
and LVpgkGFP
Male Wistar rats weighing approximately 300 g were anesthe-
tized by isoflurane gas inhalation. The right hind leg was injected
with a total of 100 ml of CMVrEpo, TREAutoR4rEPO virus
(0.4 mg p24) or 100 ml of LVpgkGFP (0.4 mg p24, corresponding
to1610
7 HeLa transducing units) in three separate injections.
Doxycycline administration, blood collection, and
analysis
Drinking water was prepared containing 200 ug/ml doxycy-
cline, 1% sucrose pH 6.0. Blood was collected every two weeks via
the tail vein under isoflurane gas anaesthesia. Hematocrit levels
were determined using a glass capillary following standard
protocols. Plasma was frozen at 220uC for determining rtTA
antibody titers.
ELISA for rat antibodies to rtTA
RtTA was expressed in 293T cells by calcium phosphate
coprecipitation. Expression of rtTA was confirmed by western
blotting. ELISA plates (Nunc) were coated overnight with 5 ug
cellular lysate (rtTA or control) per well in 50 mM carbonate
buffer pH 9.6. The wells were blocked with 1% gelatine in PBS,
washed and incubated with serial dilutions of rat plasma collected
at 2, 6, and 10 weeks following virus injection. After washing, rat
immunoglobins were detected with anti-rat IgG peroxidase
(Nordic) and o-phenylenediamine tablets (Sigma).
ELISA’s were always performed in duplicate with the same
samples applied to rtTA and control (293T cell lysate). To correct
for a specific binding, the absorbance of the control plate was
subtracted from rtTA coated plate. Rat plasma was considered to
be positive for rtTA antibodies when the absorption of samples
diluted 800 times was above the background.
Immunostaining
In vivo formaldehyde fixed and sucrose embedded muscle tissue
was snap frozen in liquid nitrogen. Sections of 7 mm were
prepared and kept at 220uC prior to use. Sections were allowed to
equilibrate at room temperature and washed three times in PBS
for 5 minutes each. Subsequently sections were incubated for hour
with a 1:100 dilution of mouse anti rat CD45 (MCA43R AbD
Serotec) in PBS/0.05% Tween-20/5% Normal goat serum/5%
Rat plasma. Then sections were washed three times, five minutes
each in PBS/0.05% Tween-20. A 1:500 dilution of goat anti
mouse IgG Alexa 594 in PBS/0.05% Tween-20/5% Normal goat
serum/5% Rat plasma was performed for one hour followed by
three wash steps in PBS five minutes each. Sections were mounted
with Vectashield with DAPI (Vector laboratories H-1200). Images
were captured at (2006) magnification using a fluorescent
microscope (Leica DMRA2).
SDS-PAGE and Western blotting
H9c2 cell lysates (50 mg) were separated on 10% SDS-PAGE
and blotted onto nitrocellulose using the Bio-Rad Miniprotean III
system. An antibody directed against the rtTA (TET02 MoBiTec)
was used at a 1:1000 dilution. An antibody directed against actin
was purchased from NeoMarkers (Ab-5) and used at a dilution of
1:1000. A 1:1000 dilution of goat anti mouse HRP (Bio-Rad 170–
6516) was used as the secondary antibody. Detection of reactive
bands on western blot was performed using the Lumi-Light
Western Blot Substrate (Roche 12 015 200 001) and blots were
analyzed using a Lumi Imager F1 and Lumi Analyst 3.1 software
(Roche).
Statistical analysis
Statistical analysis was performed using SPSS 11.0 software
using the Mann-Whitney U test. Values were determined to be
significantly different with p,0.05.
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